Anne-Marie Boothman

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · JAMA Oncology · 2020 · 616 citations · Full text

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study

Anne-Marie Boothman, Marietta Scott, M. Ratcliffe et al. · Journal of Thoracic Oncology · 2019 · 56 citations · Full text

Advanced Nsclc, Prior Therapy, Medicine +8

Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.

Marietta Scott, Michel E. Vandenberghe, Paul Scorer et al. · Journal of Clinical Oncology · 2021 · 49 citations

Breast Oncology, Immunology, Pathology +18

Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma

Magdalena Zając, Anne-Marie Boothman, Yong Ben et al. · Archives of Pathology & Laboratory Medicine · 2018 · 33 citations · Full text

Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data

Sarah R. Bujac, Angelo Del Parigi, Jennifer Sugg et al. · Diabetes Therapy · 2014 · 17 citations · Full text